Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyasu Ishida

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Japanese Journal of Clinical Oncology|April 26, 2022
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 yearsToshikazu Moriwaki, Tomohiro Nishina, Yoshinori Sakai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2020
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Japanese Journal of Clinical Oncology|April 26, 2022
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 yearsToshikazu Moriwaki, Tomohiro Nishina, Yoshinori Sakai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2020
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, et al.
Pageof 3